<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04833036</url>
  </required_header>
  <id_info>
    <org_study_id>Cetu-IRI</org_study_id>
    <nct_id>NCT04833036</nct_id>
  </id_info>
  <brief_title>c-CetuIRI Versus Ersecond-line Irinotecan s-IRI-CetuIRI</brief_title>
  <official_title>Second-line Irinotecan Combined With Cetuximab (c-CetuIRI) Versus Second-line Irinotecan Three-line Irinotecan Plus Cetuximab (s-IRI-CetuIRI) in the Treatment of Oxaliplatin and 5-FU Phase II Clinical Study of Wild-type Advanced Colorectal Cancer With RAS Gene</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary endpoint is to evaluate the progression-free survival (PFS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was designed for patients with advanced bowel cancer after first-line LOHP and&#xD;
      5-FU treatment failure. The control group was treated with second-line CPT-11+C225. The study&#xD;
      group used second-line CPT-11 single drug until the third line was CPT-11+C225. treatment.&#xD;
      Referring to the previous literature data, the PFS of the second-line treatment of&#xD;
      CPT-11+C225 is about 4 months. This study assumes that the total PFS time of C225 can be&#xD;
      extended to 7 months after the failure of second-line CPT-11 treatment compared with the&#xD;
      direct second-line combination. , set α = 0.05, β = 0.2, the expected enrollment time is 2&#xD;
      years, the follow-up time is 1 year, the 10% sample shedding rate, the total sample size is&#xD;
      about 60 cases per group, a total of 120 cases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>progression free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>through study completion, an average of half year</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>objective response rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>c-CetuIRI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Irinotecan combined with cetuximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>s-IRI-CetuIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single irinotecan first, then irinotecan plus cetuximab sequentially after PD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>180 mg/m2, ivgtt d1，q2w</description>
    <arm_group_label>c-CetuIRI</arm_group_label>
    <arm_group_label>s-IRI-CetuIRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <description>500 mg/m2, ivgtt d1，q2w</description>
    <arm_group_label>c-CetuIRI</arm_group_label>
    <arm_group_label>s-IRI-CetuIRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signing informed consent;&#xD;
&#xD;
          2. Age is greater than or equal to 18 years old;&#xD;
&#xD;
          3. Metastatic colorectal adenocarcinoma confirmed by tissue or cytopathology;&#xD;
&#xD;
          4. First-line failure to use oxaliplatin combined with fluorouracil (with or without&#xD;
             anti-angiogenic targeting drugs);&#xD;
&#xD;
          5. One or more measurable lesions, the longest diameter of the spiral CT scan is at least&#xD;
             10 mm, and the diameter of the conventional CT scan is at least 20 mm (the solid tumor&#xD;
             efficacy evaluation standard, RECIST standard, version 1.1);&#xD;
&#xD;
          6. The Eastern Cancer Cooperative Group (ECOG) has a general status score of 0-2;&#xD;
&#xD;
          7. The bone marrow capacity, liver and kidney function reached the following criteria&#xD;
             within 7 days before screening:&#xD;
&#xD;
             Absolute neutrophil count ≥ 1.5x109 / L; hemoglobin ≥ 9.0 g / dl; platelet count ≥ 80&#xD;
             x 109 / L; total bilirubin ≤ 1.5 times normal upper limit (ULN); alanine&#xD;
             aminotransferase and aspartate aminotransferase ≤ 2.5 x ULN Alkaline phosphatase ≤ 3 x&#xD;
             ULN; serum creatinine ≤ 1.5 x ULN;&#xD;
&#xD;
          8. Women of childbearing age need to take effective contraception.&#xD;
&#xD;
          9. RAS, B-RAF gene wild type&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous use of irinotecan or anti-egfr therapy for advanced colorectal cancer (e.g.&#xD;
             Cetuximab, panizumab, etc.);&#xD;
&#xD;
          2. History of HIV infection or active chronic hepatitis b or c (high copy viral DNA);&#xD;
&#xD;
          3. Patients with important organ failure or other important diseases: patients with&#xD;
             serious heart disease including congestive heart failure, uncontrolled arrhythmia,&#xD;
             angina requiring long-term medication, heart valve disease, myocardial infarction,&#xD;
             pericardial effusion with obvious symptoms, and refractory hypertension;A history of&#xD;
             severe neurological or psychiatric problems;Severe infection;Active disseminated&#xD;
             intravascular coagulation&#xD;
&#xD;
          4. Active severe clinical infection;&#xD;
&#xD;
          5. Symptomatic brain or meningeal metastasis (unless the patient was treated for &gt; for 6&#xD;
             months, had negative imaging results within 4 weeks prior to study entry, and had&#xD;
             stable tumour-related clinical symptoms at study entry);&#xD;
&#xD;
          6. Patients whose seizures require treatment (e.g. steroids or antiepileptic therapy);&#xD;
&#xD;
          7. Receiving renal dialysis;&#xD;
&#xD;
          8. Have a history of other malignant tumors within 5 years, except for cured cervical&#xD;
             carcinoma in situ or skin basal cell carcinoma, except for those whose metastasis can&#xD;
             be confirmed by pathology to be from other tumor sources;&#xD;
&#xD;
          9. Chronic intestinal diseases, infectious intestinal diseases and intestinal&#xD;
             obstruction;&#xD;
&#xD;
         10. Drug abuse and medical, psychological or social conditions may interfere with&#xD;
             patients' participation in studies or affect the assessment of their findings;&#xD;
&#xD;
         11. Any unstable condition or condition that may endanger the safety and compliance of&#xD;
             patients;&#xD;
&#xD;
         12. Pregnant or lactating women;Having fertility but not taking adequate contraceptive&#xD;
             measures;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Weijian Guo, Professor</last_name>
    <phone>86-21-64175590</phone>
    <email>mingzhuhuang0718@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>ShangHai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Jian Guo</last_name>
      <phone>13816066360</phone>
      <email>mingzhuhuang0718@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 12, 2019</study_first_submitted>
  <study_first_submitted_qc>April 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2021</study_first_posted>
  <last_update_submitted>April 2, 2021</last_update_submitted>
  <last_update_submitted_qc>April 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Weijian Guo</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

